button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)

mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - all population

versus docetaxel
atezolizumab alone vs. docetaxel 2 statistically conclusive-19%-4%-
avelumab alone vs. docetaxel 1 certainty unassessable-9% certainty unassessable+16%-
nivolumab alone vs. docetaxel 1 certainty unassessablestatistically conclusive-29% certainty unassessablestatistically conclusive-21%-
Tislelizumab vs. docetaxel 1 ---

mNSCLC - L2 - EGFR mutant metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - EGFR mutant

versus osimertinib
durvalumab plus osimertinib vs. osimertinib 1 certainty unassessable+160% certainty unassessable+10%-

mNSCLC - L2 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 negative

versus Standard of Care (SoC)
durvalumab plus tremelimumab vs. Standard of Care (SoC) 1 certainty unassessable-18% certainty unassessable-21%-

mNSCLC - L2 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) mNSCLC - L2 - PDL1 positive

versus docetaxel
atezolizumab alone vs. docetaxel 1 certainty unassessablestatistically conclusive-21% certainty unassessable-12%-
avelumab alone vs. docetaxel 1 certainty unassessable-9% certainty unassessable+1%-
pembrolizumab (10mg/kg) vs. docetaxel 2 low degree of certaintystatistically conclusive-39% low degree of certaintystatistically conclusive-28%-
pembrolizumab (2mg/kg) vs. docetaxel 2 low degree of certaintystatistically conclusive-33% low degree of certainty-25%-
versus Standard of Care (SoC)
durvalumab alone vs. Standard of Care (SoC) 1 certainty unassessable-34% certainty unassessable-27%-

non squamous - mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) non squamous cell - mNSCLC - L2 non squamous - mNSCLC - L2 - all population

versus docetaxel
nivolumab alone vs. docetaxel 1 certainty unassessablestatistically conclusive-25% certainty unassessable-7%-

squamous - mNSCLC - L2 - all population metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) squamous cell - mNSCLC - L2 squamous - mNSCLC - L2 - all population

versus docetaxel
nivolumab alone vs. docetaxel 1 certainty unassessablestatistically conclusive-38% certainty unassessablestatistically conclusive-35%-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons